Continuos
Martin Smith, chief technology officer of Pall Corporation, explores how data is finally unlocking the door to continuous bioprocessing in medicine manufacture.
The journey from tried and tested batch manufacture to continuous bioprocessing has been a long and gradual process. It began around two decades ago when manufacturers started to shift from stainless steel systems to single-use components, eventually leading to the introduction of modular systems – but the pace of change has been slow.